CG Oncology (CGON) Price Target Raised to $79 by RBC Capital

RBC Capital raised the price target for CG Oncology, Inc. (CGON) to $79 from $73 on April 27, maintaining an Outperform rating. The analysis highlights the PIVOT-006 trial as a significant upcoming catalyst, with investors anticipating data in early June that could show a 40% risk reduction and a potential 20% upside in share prices. CGON shares have seen a 62% increase year-to-date, with another rating update from BofA raising their target to $84 from $72. These factors position CGON favorably within the healthcare sector for investors as 2026 progresses.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.